ARTCLINE GmbH

ARTCLINE GmbH is a German-based startup with a focus on developing innovative therapeutic procedures for Intensive Care Medicine to treat severe infections, particularly bacterial sepsis. The company's main project, the ARTICE technology, is at the forefront of their efforts. They aim to make this technology accessible globally to medical professionals and hospitals, emphasizing safety and effectiveness as their top priorities.

With a strong background in cell biology, clinical expertise, and experience in immunology and sepsis diagnostics and therapy, ARTCLINE is dedicated to realizing its vision of pioneering immune cell-based therapy approaches. The founders and team have a proven track record in successfully bringing medical innovations from university research to industrial application.

Established in 2007, ARTCLINE GmbH has a robust network and extensive experience in developing and marketing medical devices and drugs. While specific investment details are not disclosed, the company's commitment to advancing intensive care medicine and addressing the global challenge of severe infections positions it as a compelling prospect for venture capital investment.